
Happiness is an empty beach, the wind in your ears, your best friend by your side, and 0/8 feet on the ground
✓Professor of medicine | medical oncologist | Head @EHCSMonash | Chair, @ANZUPtrials | husband, father, grandfather, blessed | want to make a positive difference

Happiness is an empty beach, the wind in your ears, your best friend by your side, and 0/8 feet on the ground

STAMPEDE and ENZARAD in High-Risk Localized Prostate Cancer. ARPI + RT/ADT for high-risk localized #ProstateCancer? @ChrisSweens1 and @jmmrad join @l_ballas to debate STAMPEDE vs ENZARAD. Both agree PSMA-only positive patients merit curative-intent intensification. #WatchNow > bit.ly/4igTxxZ

Proud to see key @ANZUPtrials #ClinicalTrials highlighted @SIU_urology #SIU2026Florence #Enzarad #BCGMM #DaslHiCap



Around 5,000 #ProstateCancer patients across 6 continents, and every voice counts. A great #APCCC2026 discussion on IRONMAN w/@Prof_IanD 🇦🇺and @CaPsurvivorship 🇺🇸 👇

Live from Lugano Series in Prostate Cancer OncoAlert🚨 × APCCC 🇨🇭 In this Episode Prof Ian Davis @Prof_IanD ( @EHCSMonash 🇦🇺 Melbourne @ANZUPtrials ) and Dr Alicia Morgans @CaPsurvivorship ( @DanaFarber 🇺🇸Boston) talk about IRONMAN, the global #ProstateCancer registry. Hearing every patient’s voice in prostate cancer 🌍 💡 Takeaways: 🔹 IRONMAN is close to its goal of about 5,000 patients at 110–115 sites on every continent except Antarctica 🔹 It collects treatment data, blood samples, concomitant medications and PROMs to study real-world sequencing and outcomes 🔹 Researchers anywhere can apply to use the data or set up sub-studies 🎓 Series Faculty @APCCC_Lugano · @BertrandTOMBAL · @ChrisSweens1 · @jmmrad · @drjefstathiou · @CaPsurvivorship · @LoebStacy · @charlesryanmd · @AarmstrongDuke · @Ecastromarcos · @LVM_Walz · @piet_ost · @Nicola_Fossati · @AnthonyMJoshua · @Prof_Nick_James · @VedangMurthy · @AttardLab · @Silke_Gillessen · @AOmlin · @ProfKHerrmann 📣 Also tagging @gu_onc · @tompowles1 · @brian_rini · @declangmurphy · @cdanicas · @neerajaiims @mzugman @AmandaNizamMD · @scocmem · @nataliagandur ·

Patient experience matters! In IRONMAN, patients’ own reports help shape future care, and they can be filled in on paper, online or by interview so no one is left out.

Can treatment intensification improve outcomes in high-risk prostate cancer, or does the benefit depend on who we treat? ascopubs.org/doi/pdf/10.1200… ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer The phase 3 ENZARAD trial evaluated adding enzalutamide to ADT and definitive radiotherapy ☢️ in 802 patients with high-risk localized or locally advanced #ProstateCancer . ➡️At eight years, metastasis-free survival was 74% versus 72%, showing no statistically significant overall benefit. ➡️However, patients receiving pelvic nodal radiotherapy demonstrated a notable benefit (HR 0.47). Grade 3–5 adverse events were identical at 46%, highlighting important questions about patient selection and treatment intensification. @ChrisSweens1, @DocJarad, @RayMcDermott1, @MartinStockler, @Prof_IanD, @DrPaulNguyen @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

VIDEO: Xtandi instead of an older antiandrogen with RT + 2 yrs ADT in high-risk prostate cancer? ENZARAD (JCO, Oct 24, 2026): 8-yr MFS 74% vs 72%, HR 0.88 🧬⚠️ 👉 oncologytube.com/xtandi-enza… 🔹 Phase 3, open-label, n=802: enzalutamide 24 mo vs older NSAA 6 mo, both with RT + 24 mo ADT; median follow-up 92 mo 🔹 8-yr OS 83% vs 80% (HR 0.87); PSA PFS favored enzalutamide (HR 0.78) 🔹 Exploratory subgroups (hypothesis-generating only): MFS HR 0.47 with planned pelvic nodal RT, 0.43 in cN1 ENZARAD does not support routinely adding enzalutamide in unselected high-risk disease. First presented at ESMO 2025 (LBA86). @OncoAlert @Prof_IanD @ChrisSweens1 @DocJarad @DrLesterColl @Adam_Weiner535 @zklaassen_md @Kenrickng1 @brookmans76 @HimanshuNagarMD @AndreaNecchi @TonyFelefly @DrPaulNguyen @VedangMurthy @piet_ost @DrSrinivas_C @BourlonMaite @Silke_Gillessen @DrSpratticus @PCaParker @PaulSargos @_ShankarSiva @PBlanchardMD @NicholasZaorsky @ChadTangMD @EAntonarakis @DrRanaMcKay @neerajaiims @Prof_Nick_James @WallisCJD @Albert0Briganti @amerseburger @ChapinMD @DrScottTagawa @PBarataMD #ProstateCancer #PCSM #GUOnc #RadOnc #MedOnc #OncologyTube

Dear Lord I've been failing to tag @ThePCCTC who were absolutely pivotal to the #DASLHiCaP trial!


How could DASL-HiCaP influence treatment decisions for patients with high-risk #ProstateCancer? Following #ESMO26, Dr. Tamim Niazi shares his perspective on current treatment and where darolutamide could fit into future practice. ▶️ Watch the full video: mirrorsmed.org/a2p-pca-esmo-… @OncoAlert @niazi_Dr7


🔬 Can adding an androgen receptor inhibitor to ADT and radiotherapy improve metastasis-free survival in very high-risk localised prostate cancer? New Phase 3 interim results from DASL-HiCaP suggest a significant benefit. 📊 LBA4 – DASL-HiCaP (ANZUP1801): Darolutamide with ADT and definitive or salvage locoregional radiotherapy cslide.ctimeetingtech.com/es… Darolutamide added to ADT and locoregional radiotherapy significantly improved metastasis-free survival in patients with very high-risk localised or biochemically persistent/recurrent prostate cancer. At four years, metastasis-free survival was 95% versus 88% with placebo (HR 0.42; p=0.0001). ✅ These findings support treatment intensification, although longer follow-up is needed to establish whether this benefit translates into improved overall survival. #ProstateCancer @niazi_Dr7, @Prof_IanD, @ChrisSweens1, @AlisonZhangMBBS, @seanmmcbride, @DocJarad, @DavePryorRO, @MartinStockler @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Voting is compulsory in Australia. It sometimes feels a bit inconvenient or like choosing the least worst option, but if you don’t vote then you have no right to complain if bad people get elected. Choosing not to vote when your democracy is crumbling would be a strange decision.